Form 4: Schrodinger CAO Sells Shares for Tax Obligations

Schrodinger's Chief Accounting Officer, Jenny Herman, sold common stock to cover tax liabilities from RSU vesting, not as a discretionary trade.

Summary

• Jenny Herman, Chief Accounting Officer (CAO) of Schrodinger, Inc. (SDGR), reported sales of common stock.
• The transactions occurred on March 5, 2026, and March 6, 2026.
• These sales were non-discretionary, executed pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 11, 2023.
• The purpose of the sales was to satisfy withholding tax liabilities incurred upon the vesting of restricted stock units (RSUs).
• On March 5, 2026, 775 shares were sold at a weighted average price of $12.846 per share, with prices ranging from $12.73 to $12.96.
• On March 6, 2026, 608 shares were sold at a weighted average price of $12.842 per share, with prices ranging from $12.715 to $12.92.
• Following these transactions, Jenny Herman beneficially owns 34,804 shares directly, which includes an aggregate of 22,597 unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction to cover tax liabilities from RSU vesting, not an indication of a change in management's outlook.

Positives

• The sales were non-discretionary and pre-scheduled under a Rule 10b5-1 plan, indicating a lack of personal timing or market sentiment influence.
• The purpose of the sales was to cover tax liabilities from RSU vesting, a routine event for executives receiving equity compensation.
• The officer retains a significant beneficial ownership of 34,804 shares, including 22,597 unvested RSUs, aligning her interests with long-term shareholder value.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Management Comments

• This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 11, 2023, represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that routine sales by corporate officers to cover tax obligations upon RSU vesting are common practice across industries and are generally not indicative of management's sentiment towards the company's future prospects. Such transactions are often pre-scheduled under Rule 10b5-1 plans to avoid accusations of insider trading.

Comparison to Industry Standards

• This type of transaction, a non-discretionary sale to cover tax liabilities from RSU vesting, is standard practice for executives in publicly traded companies across various sectors, including biotechnology and software, such as those seen at companies like Moderna (MRNA) or Adobe (ADBE).
• The use of a Rule 10b5-1 plan, adopted well in advance (March 11, 2023, for sales in March 2026), aligns with best practices for corporate governance, similar to plans implemented by executives at major tech firms like Microsoft (MSFT) or pharmaceutical giants like Pfizer (PFE) to ensure compliance and transparency.
• The remaining beneficial ownership, including a significant portion of unvested RSUs, suggests continued alignment of the officer's interests with long-term shareholder value, consistent with executive compensation structures at peer companies in the life sciences software space.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related sale by an officer, not a signal of reduced confidence. The officer retains significant equity.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by a corporate officer to cover tax obligations arising from RSU vesting, executed under a pre-established 10b5-1 plan. Such transactions are common and do not typically signal a change in the company's fundamentals or management's confidence. Therefore, the filing itself does not provide new information that would warrant a change in investment recommendation; a "hold" stance is appropriate as the core investment thesis remains unchanged based on this specific disclosure.

Keywords

Schrodinger, SDGR, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan, Corporate Officer